Validation of novel and sustainable RNase inhibitors for biomedical research and clinical diagnostics
| Reference number | |
| Coordinator | SEQURNA AB |
| Funding from Vinnova | SEK 300 000 |
| Project duration | November 2023 - October 2024 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Impact Startups autumn 2023 |
Important results from the project
We successfully met two of the project’s three main goals: gathering invaluable insights from beta-tester collaborations and scaling up production. The third goal, ISO certification, is on track for completion by Q1 2025 as a direct outcome of the project. Vinnova´s financing allowed us to engage closely with early users and increase production capacity. Positive feedback from collaborators and increasing sales have been instrumental in securing market presence.
Expected long term effects
This project funding was an incredibly helpful way to get us from the beta/pilot stage into a profitable venture that generates revenue through product sales. Through this endeavor we have managed to reach a point where were are actually profitable. This is a big milestone for us and represents how successful we have become. Additionally, the ISO-9001 compliance and certification will help us in the future to be seen as a reliable and established company internationally.
Approach and implementation
At the start of the project, we focused on refining production processes, including packaging, shipping supplies, and setting up an assembly facility. We gained connections with new beta testers and continued follow-up with existing ones, maintaining regular engagement through pilot sales and into the full-scale rollout of our product. During this time, we also collaborated with major biotech companies integrating our products into their offerings, expanding our reach and impact in the industry.